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Abstract: Eosinophils are known to express cyto-
kines capable of promoting fibrosis. Interleukin-5
(IL-5) is important in regulating eosinophilopoiesis,
eosinophil recruitment and activation. Lung IL-5
expression is elevated in pulmonary fibrosis,
wherein the eosinophil is a primary source of
fibrogenic cytokines. To determine the role of IL-5
in pulmonary fibrosis, the effects of anti-IL-5 anti-
body were investigated in a model of bleomycin-
induced pulmonary fibrosis. Fibrosis was induced
in mice by endotracheal bleomycin treatment. Ani-
mals were also treated with either anti-IL-5 anti-
body or control IgG. Lungs were then analyzed for
fibrosis, eosinophil influx, chemotactic activity,
and cytokine expression. The results show that a
primary chemotactic activity at the height of eosino-
phil recruitment is IL-5. Furthermore, anti-IL-5
antibody caused significant reduction in lung eosino-
philia, cytokine expression, and fibrosis. These
findings taken together suggest an important role
for IL-5 in pulmonary fibrosis via its ability to
regulate eosinophilic inflammation, and thus eosino-
phil-dependent fibrogenic cytokine production.
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INTRODUCTION
Pulmonary inflammation, bronchial hyperrreactivity, and eosino-
phil infiltration into the airway are pathological features of
asthma [1–3]. Analysis of lung tissue from asthmatic patients
who died demonstrated tissue eosinophilia basement mem-
brane thickening and mucus plugging [4, 5]. There is a
suggestion that the airway wall thickening may be a fibrotic
response [6]. However, it is unclear whether eosinophils
directly play a role in pulmonary fibrosis. There is substantial
evidence for the presence of eosinophils in lung fibrotic lesions
and their ability to elaborate cytokines [7–16]. More recently,
studies of a rodent model of bleomycin-induced pulmonary
fibrosis show that infiltration by eosinophils parallels the
development of the fibrotic lesion, and that they represent a key
source for cytokines such as monocyte chemotactic protein-1
(MCP-1), transforming growth factor b1 (TGF-b1), and interleu-
kin-5 (IL-5) [8, 9, 16]. IL-5 is important in eosinophil
accumulation in the lung [17]. Based on these previous
observations, the importance of eosinophils in pulmonary
fibrosis is suggested by two lines of evidence. First, these cells
are now known to be important sources of cytokines with known
inflammatory and fibrosis-promoting activities [8–12, 16],
representing a key cellular source of TGF-b1 and MCP-1 (the
JE gene product in mice) as well as a significant source of IL-5
in bleomycin-induced pulmonary fibrosis [8, 9, 16]. Second, the
presence of eosinophils in lungs of patients with pulmonary
fibrosis correlates with worst prognosis and/or resistance to
therapy [18, 19]. Thus there is compelling evidence to suggest
that eosinophils may play an important role in pulmonary
fibrosis via its ability to elaborate the cytokines capable of
driving the fibrogenic response.
The mechanism for recruitment of eosinophils into the lung
has been extensively studied primarily in animal models of
airway reactivity. These studies have identified the importance
of certain cytokines and chemokines in this process. Among the
many cytokines, IL-5 is the most closely correlated with
eosinophilia, presumably because of its role in eosinophilopoi-
esis, eosinophil chemoattraction, prolongation of eosinophil
survival, and eosinophil activation [20–22]. In addition, admin-
istration of antibody to IL-5 inhibits eosinophil recruitment into
bronchoalveolar lavage fluid of antigen-challenged previously
sensitized animals [23–27]. Furthermore, lung IL-5 expression
is elevated at sites of active fibrosis in the bleomycin model,
with most of the expression localized to T cells and secondarily
to eosinophils, and the kinetics of its up-regulation correlates
with that for lung eosinophil infiltration [16, 28]. There are,
however, other eosinophil chemoattractants that have been
more variably reported to be involved in lung eosinophil
recruitment. Among these, IL-4, RANTES, macrophage inflam-
matory protein 1a (MIP-1a), and most recently, eotaxin have
been reported to have chemotactic activity for eosinophils
[29–31]. However, the role of these cytokines has not been
directly examined in vivo in pulmonary fibrosis-associated lung
eosinophil infiltration.
This investigation was designed to extend these IL-5 studies
to test the hypothesis that IL-5 may drive pulmonary fibrosis by
its ability to recruit eosinophils into the lung and up-regulating
their expression of cytokines previously demonstrated to be
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important in fibrosis. To test this hypothesis, the effects of
anti-IL-5 antibodies were investigated to evaluate their ability
to inhibit lung tissue eosinophil chemotactic activity, pulmo-
nary eosinophilia, cytokine expression, and fibrosis in a murine
model of bleomycin-induced lung injury.
MATERIALS AND METHODS
Animals and tissue sampling
Specific pathogen-free, female CBA/J mice weighing 20–25 g were obtained
from Jackson Labs (Bar Harbor, ME). These animals arrived in filtered cages
and were maintained in clean animal quarters separate from other laboratory
animals. Mice were randomly assigned into 12 different groups of 15 animals
each. Six of these groups were treated on day 0 with 26 µg/mouse of bleomycin
(Blenoxanet, Bristol-Myers Co., Evansville, IN) by endotracheal injection, as
previously described [8, 9]. The remaining groups, representing non-fibrotic
control animals, received sterile saline on day 0. On days 0, 3, and 5, two
groups each of the control and bleomycin-treated groups were given intrave-
nous injections of 1 mg/mouse of a monoclonal rat anti-mouse IL-5 antibody
(TRFK-5), prepared as previously described [32, 33]. This antibody at this dose
has previously been found to be effective in suppressing eosinophilic inflamma-
tion in mice [20]. Preliminary studies using 0.1 mg/mouse of TRFK-5
antibodies failed to inhibit lung eosinophilia or fibrosis (data not shown). Two
other groups each of the control and bleomycin-treated groups were injected
with the same amount of control IgG. The remaining two groups from both
control and bleomycin-treated groups received equal volumes of sterile saline
intravenously.
Groups of animals containing one each of the control and bleomycin-treated
groups with or without anti-IL-5 antibody injections were killed [8, 9] on days 7
and 14 after treatment. At each time point, the lungs from 10 animals per group
were used for extraction of mRNA for Northern hybridization analysis and
hydroxyproline assay. For the remaining animals in each group, the lungs were
rapidly dissected out and immediately inflated with phosphate-buffered saline
(PBS), 10% neutral buffered formalin, pH 7.2, or methacarn (methanol,
chloroform, glacial acetic acid 6:3:1 v/v). After overnight fixation, lungs were
embedded in paraffin [8, 9]. PBS-inflated lung tissues were used for frozen
sections. Three-to four-micrometer serial sections of formalin, methacarn-fixed
tissue or frozen specimens (using AO Microtome) were used for routine
histology or immunohistochemistry [8, 9].
For studies of eosinophil chemotactic activities, separate groups of animals
(five per group) were treated with saline or bleomycin on day 0 and killed at
various time points. The lungs after rapid perfusion with PBS were homog-
enized in PBS supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF),
and the homogenate centrifuged at 20,000 g for 30 min at 4°C. The supernate
was collected and stored frozen until assay for eosinophil chemotactic activity.
RNA extraction
At each indicated time point, lungs from control and treated animals were
rapidly perfused with sterile PBS via the right ventricle until blanched. The
lungs were rapidly dissected out, promptly suspended into guanidine isothiocya-
nate solution [8], and rapidly homogenized with a polytron (Brinkmann
Instruments, Westbury, NY). Total RNA was isolated as previously described
and the poly(A)-rich fraction purified by oligo (dT) cellulose chromatography
[34–38].
Northern hybridization
To determine and quantify lung IL-5, TGF-b1, and MCP-1 mRNA expression,
Northern hybridization analysis was performed on total RNA isolated from
mouse lungs of treated and control groups as previously described [34–38].
Briefly, equal amounts of total lung RNA (20 µg/lane) were electrophoresed on
1.0% agarose gels containing formaldehyde. Uniformity of RNA concentration,
and thus equal loading, was confirmed by examination of 18S and 28S rRNA
bands on separate ethidium bromide-stained mini gels under ultraviolet light.
The separated RNA was then transferred overnight onto nitrocellulose filters,
and the blots were confirmed for equal loading by viewing the 28 and 18S rRNA
bands after ethidium bromide staining. Blots were then baked, prehybridized,
and hybridized with 32P-labeled oligonucleotide antisense probes for mouse
IL-5, TGF-b1, and MCP-1. The sequences for the 30-mer oligonucleotide
antisense probes were as follows: mIL-5, 58-TCCAGGACCTGCCTCGTCCTCC-
GTCTCTCC-38 [16]; TGFb1, 58-GAACTTGGCATGGTAGCCCTTGGGCTC-
GTG-38 [39]; MCP-1, 58 TGTCTGGACCCATTCCTTCTTGGGGTCAGC-38
[40]; and GAPDH, 58-CACCCTGTTGCTGTAGCCGTATTCATTGTC-38 [41].
These probes were synthesized on an automated DNA synthesizer and
purified by high-performance liquid chromatography followed by sodium
acetate and ethanol precipitation. After overnight hybridization at 56°C, blots
were washed [8, 9, 16, 34–38], and autoradiograms developed from these blots
were quantitated using an Ambis Optical Imaging System (Ambis, San Diego,
CA) [32–38]. The blots were reprobed with the GAPDH probe to confirm
equivalent RNA loading.
Lung hydroxyproline assay
The total lung hydroxyproline concentration was determined as previously
described [42].
Antibodies and immunohistochemistry
Rat monoclonal anti-mouse IL-5 was prepared as previously described [25, 27,
32, 33] or purchased commercially from Genzyme (Cambridge, MA). The
commercial antibody was used only for the in vitro chemotactic assays. Rat and
rabbit affinity-purified non-immune IgG, chromotrope 2R, and toluidine blue
were purchased from Sigma Chemical Co. (St. Louis, MO). Polyclonal rabbit
anti-TGF-b antibody (AB-100-NA) was from R & D Systems (Minneapolis,
MN), and is a pan-specific antibody that recognized all the major TGF-b
isoforms. Hamster monoclonal anti-mouse MCP-1 antibody was from Pharmin-
gen (San Diego, CA). Antibodies to MIP-1a and RANTES were prepared as
previously described [43]. Anti-human eosinophil major basic protein antibody
(BMK-13, IgG1) was from Monosan (Uden, The Netherlands). Anti-murine
eotaxin antibodies were purchased from PeproTech (Rocky Hill, NJ). Secondary
antibodies and related reagents were purchased from Vector Laboratories
(Burlingame, CA). Mouse myeloma IgG1 was from Zymed (South San Fran-
cisco, CA).
Immunohistochemistry for analysis of IL-5, TGF-b, and MCP-1 protein
expression and cellular localization was performed using two different methods,
alkaline phosphatase and immunoperoxidase. The alkaline phosphatase method
was undertaken as previously described [44] with some modification. Briefly,
sections were deparaffinized, rehydrated, and digested with proteinase K,
followed by blocking with normal rabbit or goat serum to reduce nonspecific
binding of the secondary antibody. The primary antibodies were added at the
following concentrations: anti-IL-5 at 1:5 to 1:10 dilution, anti-TGF-b 10
µg/mL, anti-MCP-1 5 µg/mL, and BMK-13 at 1:10 dilution. They were then
allowed to incubate at 4°C overnight. The appropriate biotinylated and
affinity-purified secondary antibodies were then added and allowed to incubate
for 1 h at room temperature, followed by addition of a red substrate (Vector
Labs, Burlingame, CA) plus levamisole solution to inhibit endogenous alkaline
phosphatase.
Immunoperoxidase staining was done as previously described [44–46] with
some modification, using microwave procedures. Briefly sections were deparaf-
finized, rehydrated, washed in PBS, and endogenous peroxidase activity in
section was inactivated with 3% H2O2. After washing with deionized water,
slides were microwaved in deionized water for 2 min and 30 s, and washed for
1 min with 70–80°C deionized water. After repeating this twice, the slides were
washed with deionized water and PBS, followed by incubation with normal
rabbit or goat serum to reduce nonspecific binding of secondary antibody. The
primary and secondary antibodies were added in the same manner as the
alkaline phosphatase method, followed by avidin-biotin amplification (ABC
Elite) for 30 min. After incubation with the DAB substrate, the reaction product
was enhanced by exposure to DAB enhancing solution, followed by counterstain-
ing with hematoxylin, and sequential dehydration. Mouse spleen cells stimu-
lated with Con A [47] were used as positive controls for the anti-IL-5 antibody.
Negative controls included (1) substitution of primary antibody for correspond-
ing nonimmune IgG isotype, (2) omission of primary antibodies, and (3)
omission of respective secondary antibodies.
General histological appearance of lung tissue was assessed after routine
hematoxylin and eosin (H & E) staining. Eosinophil was identified by staining
with carbol chromotrophe 2R as previously described [8], and by their
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polymorphonuclear morphology. IL-5-, TGF-b-, and MCP-1-positive cells were
identified by immunostaining with their respective specific antibodies [8, 9,
16].
Morphometric analysis
The number of lung eosinophils were counted in tissue sections stained with
either chromotrope 2R or BMK-13 antibody as previously described [8, 9].
IL-5- or TGF-b-positive cells were similarly counted by light microscopy using
the 340 objective and ocular grid. At least 30 randomly chosen noncontiguous
and non-overlapping high power fields were counted in each lung segment. Five
segments from each mouse lung and a total of five mice per group were
analyzed. Cell counts were expressed as the number of cells per high power
field.
Eosinophil chemotactic assay
Lung extracts from control and bleomycin-treated animals were prepared as
described above for assay and identification of eosinophil chemotactic activity.
Mouse peritoneal eosinophils were isolated from mice previously sensitized to,
and challenged with schistosome egg antigen as previously described [47–49].
The final preparation was at least 80% eosinophils, with the remainder
comprised of neutrophils and mononuclear cells. Chemotactic assay was
performed in microwell modified Boyden chambers using 5-µm pore size
polycarbonate filters as previously described [31, 50]. Various dilutions of the
lung extracts were analyzed for eosinophil chemotactic activity. Migrated cells
in the bottom surface of the filter were counted after identification as
eosinophils with the use of chromotrope 2R staining, and expressed as cells
migrated per high power field. A minimum of 100 cells were counted in
randomly selected, non-overlapping high power fields. After subtracting the
negative control value (migration to media alone), the activity was expressed as
a percentage of the activity of the positive control (50 ng/mL MIP-1a). A unit of
activity was defined as 1% of the activity found in the positive control sample.
Checkerboard analysis was used to determine chemotactic versus chemokinetic
activities.
To identify the nature of any detected chemotactic activity, selected lung
extract samples with high activity were preincubated for 1 h with specific
antibodies (100 µg/mL) to IL-4, IL-5, RANTES, eotaxin, MIP-1a, or a
combination of antibodies. These pretreated samples were then used in the
chemotactic assay to see if any of these antibodies or combination of antibodies
were able to inhibit the eosinophil chemotactic activity. To confirm specificity
of the inhibition, negative controls using non-immune isotype-matched IgG or
sera were included.
Statistical analysis
All data were expressed as means 6 SE, with N being the number of animals for
each group. Differences between mean values from the various treatment and
control groups were assessed for statistical significance by analysis of variance
followed by post hoc analysis using Scheffé’s test for comparison between any
two groups [8, 9]. A P value , 0.05 was considered to indicate statistical
significance.
RESULTS
Lung eosinophil chemotactic activity
There is substantial evidence supporting a role for IL-5 in lung
eosinophil recruitment in models of hyperreactive airway
disease [16, 24, 47]. However, the role of other cytokines and
other non-protein chemoattractants is not as clear or consis-
tently documented. Evidence for any of these factors in
eosinophil recruitment in pulmonary fibrosis is lacking. To
identify the nature of any eosinophil chemotactic activity, lung
tissue extracts from bleomycin-injured and control lungs were
first examined for the presence of such activity. The results of
eosinophil chemotactic assays of these lung extracts show
detectable activity in samples from both control and bleomycin-
treated mice at all time points examined (Fig. 1). The relatively
low levels of activity on day 1 after bleomycin injury became
significantly elevated on days 2, 4, and 8 in the bleomycin-
treated animals, and only on days 2 and 4 for the saline-treated
control animals. However, the activities at all time points were
greater in the bleomycin-treated lung samples relative to those
from the saline controls, with the difference being statistically
significant for days 2, 4, and 8. The activity remained high on
day 8 for the bleomycin-treated lung extracts, but declined to
baseline levels for the saline controls. Checkerboard analysis of
lung extracts from day 4 bleomycin-treated animals revealed
the activity to be chemotactic with only minimal chemokinetic
activity (Table 1).
Based on these results, lung extract samples from the day 4
time point were chosen for further study in order to identify the
source of this activity. Both control and bleomycin-treated
samples were preincubated with the indicated cytokine antibod-
ies or their respective control immunoglobulins, and then
assayed for eosinophil chemotactic activity. Based on previous
studies of their chemotactic activity and the availability of
antibodies directed against these proteins, antibodies against
MIP-1a, eotaxin, RANTES, IL-4, and IL-5 were used for this
experiment. The results indicated that all five antibodies had
some specific inhibitory activity against the chemotactic activ-
ity in both control and bleomycin-treated samples (Fig. 2).
Against the activity in control samples, these antibodies were
able to inhibit from ,40%, for anti-RANTES antibody, up to as
high as 52% for the anti-IL-5 antibody. The inhibition by these
antibodies was greater against the bleomycin-treated samples,
Fig. 1. Kinetics of lung eosinophil chemotactic activity. Lung extracts from
control and bleomycin-treated mice were prepared at the indicated time points
and then assayed for eosinophil chemotactic activity as described in Materials
and Methods. Each data point represents the mean of activity obtained from five
different mice per group, and standard error (SE) bars are shown. The activities
in samples from bleomycin-treated animals were significantly (P , 0.05)
higher than those from control mice at all time points examined after day 1.
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ranging from 50% for anti-RANTES antibody to .80% for
anti-IL-5 antibody. A combination of anti-eotaxin and anti-IL-5
antibodies did not significantly increase the inhibition by
anti-IL-5 alone. Similarly, a combination of all antibodies failed
to significantly increase the inhibition of activity by anti-IL-5 or
anti-eotaxin alone (data not shown). The respective IgG-
negative controls did not have a significant effect on the
observed chemotactic activities of both control and bleomycin-
treated lung samples (data not shown). Thus the chemotactic
activity in the bleomycin-treated lungs was both qualitatively
and quantitatively different from that in the control lung
samples. The greatest suppression in the bleomycin lung
samples by the anti-IL-5 and anti-eotaxin antibodies suggested
that these two cytokines may be the key eosinophil chemoat-
tractants (or as co-chemotactins) in bleomycin-injured lungs,
although the contribution of MIP-1a and IL-4 were not
insignificant.
Effect of anti-IL-5 antibodies on lung eosinophils,
histopathology, and fibrosis
Examination of fixed lung tissue from control mice treated with
control IgG or anti-IL-5 antibodies at various time points did
not show any sign of inflammation or other morphological
changes (data not shown). In contrast, lungs from bleomycin
treated animals injected with control IgG showed severe
distortion of lung parenchyma, which became more extensive
on day 14. This was characterized by loss of normal alveolar
architecture by prominent disorganized thickening of the
alveolar septae, infiltration of the alveolar space by organizing
inflammatory infiltrate and fibroblasts. Peribronchiolar, perivas-
cular, and submesothelial inflammatory and fibrotic lesions
became prominent with dramatic increases in lung cellularity.
In accord with previous studies [8, 9, 16, 25], immunostaining
of frozen lung sections with BMK-13 antibody (data not shown)
or histochemical staining with chromotrope 2R of formalin or
methacarn fixed lung tissue, showed significant numbers of
eosinophils at days 7 (data not shown) and 14 in bleomycin-
treated mice (Fig. 3, A and C). The eosinophils were clustered
in cellular areas where early fibrosis was evident (Fig. 3A). In
view of the results from the chemotactic studies, the effects of
anti-IL-5 antibodies on eosinophil recruitment in vivo and
fibrosis were examined. Lungs from bleomycin-treated animals,
which were also treated with anti-IL-5 antibodies, showed
markedly reduced inflammation and fibrosis on day 14 (Fig.
3B). Although the antibodies did not completely suppress
inflammation at this time point, it was much less than that seen
in lungs from bleomycin-treated animals receiving control IgG
(Fig. 3A). Examination of chromotrope-2R-stained sections
revealed that lungs from bleomycin-treated animals that also
received anti-IL-5 antibody contained noticeably fewer eosino-
phils distributed in cellular areas, which were much smaller
than those treated with control IgG, and with diminished
evidence of early fibrosis (Fig. 3, B and D). Morphometric
analysis of the lung tissue sections confirm the reduction in
eosinophil recruitment by anti-IL-5 treatment at both the day 7
and day 14 time points (Fig. 4). Thus neutralization of IL-5
activity was effective in inhibiting eosinophil recruitment to the
lung, which correlated with suppression of pulmonary inflamma-
tion and fibrosis. Control IgG had no detectable effects on the




(%) < 0 20 40 60 80
0 1.94 6 0.12 2.78 6 0.19 1.82 6 0.29 1.88 6 0.19 1.72 6 0.14
20 15.1 6 0.40 5.14 6 0.31 3.62 6 0.26 2.84 6 0.3 2.42 6 0.28
40 26.04 6 0.72 17.24 6 0.30 5.66 6 0.31 3.8 6 0.42 3.28 6 0.10
60 18.90 6 0.53 21.26 6 0.78 17.74 6 0.54 5.42 6 0.36 4.82 6 0.48
80 18.34 6 0.7 17.24 6 0.33 20.7 6 0.48 16.66 6 0.48 5.92 6 0.30
Lung extracts from day 4 bleomycin-treated animals were placed in the upper (Top) and lower (Bottom) compartments of the modified blind-well Boyden chambers
at the indicated concentrations. Eosinophils were placed in the upper compartment. The results were expressed in units of activity and shown as means 6 SE with
N 5 5.
Fig. 2. Effects of various anti-chemokine antibodies on lung eosinophil
chemotactic activity. Lung extract samples from day 4 control and bleomycin-
treated mice were pretreated with the indicated antibody or combination of
antibodies, and then assayed for eosinophil chemotactic activity. The results
were expressed as a percentage of the respective control mean value using the
corresponding immunoglobulin control for each antibody. The various control
IgGs had no significant effects on the chemotactic activity (data not shown). The
means 6 SE of triplicate assays are shown.
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morphology of saline or bleomycin-treated lungs (data not
shown).
To confirm the morphological evidence of reduced pulmo-
nary fibrosis, separate lung tissue samples were subjected to
hydroxyproline assay. The results showed that the lung hydroxy-
proline content of control mice treated with control IgG were not
significantly different from those treated with anti-IL-5 antibod-
ies (Fig. 5). In contrast, lungs from bleomycin-treated animals
injected with control IgG showed significant increases in lung
hydroxyproline content (Fig. 5) consistent with the histopatho-
logical findings (Fig. 3). Treatment with anti-IL-5 antibodies
significantly suppressed the bleomycin-induced increase in
lung hydroxyproline content (Fig. 5). Control IgG had no
significant effect on hydroxyproline content of control or
bleomycin-treated lungs (data not shown).
Effects on lung cytokine expression
Previous studies have shown that eosinophils represent a key
source of several fibrogenic cytokines, such as TGF-b1 and
MCP-1 [1–3, 5, 6, 8, 9, 15, 16]. Because anti-IL-5 can
effectively suppress eosinophil recruitment, the effects of this
antibody on lung cytokine expression after bleomycin-induced
injury were examined to assess the contribution of eosinophils
to overall lung cytokine expression. Lung mRNA content for
two cytokines, namely TGF-b1 and MCP-1, were quantitated by
Northern blot analysis. Consistent with previous studies [8, 9],
the results show significant increases in expression of both
cytokines as a result of bleomycin-induced lung injury in
animals treated with control IgG (Fig. 6). These increases were
inhibited by treatment with anti-IL-5 antibodies (Fig. 6).
Fig. 3. Effects of anti-IL-5 antibody treatment on lung histopathology. Lung sections from day 14 control and treated animals were stained with chromotrope 2R to
identify eosinophils and counterstained with hematoxylin as described in Materials and Methods. Representative lung sections from bleomycin-treated animals and
injected with either control IgG (A, C) or anti IL-5 antibody (B, D), are shown. Low-power views (original magnification 3200) show inflammatory infiltrate and early
fibrosis in control lungs (A), which were substantially diminished in anti-IL-5 antibody-treated mice (B). A higher-magnification (original magnification 3400) view
of the cellular areas show dense clusters of polymorphonuclear cells, which stained red with the chromotrope 2R (inset in C), which became markedly reduced by the
anti-IL-5 antibody treatment (D and inset).
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To explore the effects of the anti-IL-5 antibody on the
cellular distribution of bleomycin-induced lung TGF-b1 and
IL-5 expression, immunohistochemical evaluation of cytokine
expression was performed. Immunostaining with anti-IL-5
antibody of lung sections from bleomycin-treated mice showed
clusters of IL-5-expressing cells in fibrotic areas. The predomi-
nant IL-5-expressing cells were mononuclear cells, consistent
with the previous observation that T lymphocytes are the
primary source of IL-5 in bleomycin-injured murine lungs,
whereas the eosinophil is a secondary source [16, 51–57].
When lung sections from bleomycin- and anti-IL-5-treated
animals were examined, there was a substantial decrease in the
number of IL-5-expressing cells, which was confirmed by
morphometric counting (Fig. 7A). Control lungs from mice
receiving control IgG or anti-IL-5 antibody did not show any
detectable IL-5 expression.
Immunostaining with anti-TGF-b and anti-MCP-1 antibod-
ies revealed similar results. As previously reported [8, 9, 16],
there was a substantial increase in the number of cells
expressing these cytokines in bleomycin-injured lungs, which
was also inhibited by treatment with anti-IL-5 antibody as
confirmed by morphometric counting of cytokine-positive cells
(Fig. 7, B and C, respectively).
DISCUSSION
A previous study has demonstrated that induction of lung IL-5
mRNA and protein expression in bleomycin-injured lungs is
primarily localized to T lymphocytes and secondarily to eosino-
phils at sites of active fibrosis [16]. Furthermore, at early time
points during the period of active fibrosis, expression of TGF-b1
and MCP-1 is seen primarily in eosinophils [8, 9]. Considering
the importance of these cytokines to pulmonary inflammation
and fibrosis, plus the importance of IL-5 in eosinophil recruit-
ment [31, 55–59], this study was undertaken to see whether
neutralization of endogenous IL-5 activity could down-regulate
lung eosinophilia associated with bleomycin-lung injury and
the consequent fibrotic response. Initial studies confirmed the
importance of IL-5 as an important eosinophil chemotactic
factor or cofactor in bleomycin-injured lung tissue because
anti-IL-5 antibody inhibited most of the activity found in
extracts of injured lungs. Significant inhibition was also evident
with antibodies to eotaxin, MIP-1a, and IL-4, but when these
were added to the anti-IL-5 antibody, no significant further
inhibition from that obtained by the anti-IL-5 antibody alone
was observed. This seems to favor the role of IL-5 as a cofactor
in the chemotactic activity present in the lung extracts. Using
TRFK-5, a neutralizing monoclonal antibody to murine IL-5
[20, 32, 33, 60] in a murine model of bleomycin-induced lung
injury and fibrosis [8, 9], the results show significant reduction
in severity of lung inflammation, tissue damage, and fibrosis byFig. 4. Effects of anti-IL-5 antibody on lung eosinophil recruitment. Eosino-
phils in lung sections from bleomycin-treated mice with or without anti-IL-5
antibody treatment were identified by chromotrope 2R staining and polymorpho-
nuclear morphology, and counted as described in Materials and Methods.
Results were expressed as the number of cells per high power field. Values
represent means 6 SEM (N 5 5 per group). Antibody treatment significantly
reduced (P , 0.01) the number of lung eosinophils at both time points
examined.
Fig. 5. Effects of anti-IL-5 antibody on lung hydroxyproline content. Pulmo-
nary fibrosis was biochemically assessed by measurement of lung hydroxypro-
line content on the indicated days post-bleomycin treatment. Results were
expressed as total lung hydroxyproline content. Means 6 SE (N 5 5) for each
experimental group are shown. ‘‘Control’’ treatment group consisted of mice
treated with control IgG. Bleomycin-induced pulmonary fibrosis was signifi-
cantly inhibited by treatment with anti-IL-5 antibody. The hydroxyproline
contents of control untreated and bleomycin-treated (without control IgG or
anti-IL-5) lungs were 154 6 9 and 302 6 17 µg, respectively. These were not
significantly affected by treatment with control IgG.
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this antibody. This effect was accompanied by inhibition of
bleomycin-induced lung eosinophil influx, cytokine expression,
and elevation in lung hydroxyproline content. The antibody
effect was specific because control IgG did not have such an
inhibitory effect. Taken together these findings provide some
support for the conclusion that IL-5 is involved in the lung
eosinophilia seen in mice undergoing bleomycin-induced pul-
Fig. 6. Lung cytokine mRNA expression by Northern blotting analysis. Total
lung RNA from IgG or anti-IL-5 antibody-treated control and bleomycin-
treated animals at the indicated time points were subjected to Northern blot
analysis for determination of TGF-b1 (A) and MCP-1 (B) mRNA as described in
Materials and Methods. The autoradiograph for each cytokine mRNA is shown
in the inset in the upper right portion of each panel. The corresponding 28S and
18S ribosomal RNA bands, and the GAPDH mRNA results are shown for the
day 14 specimens to document uniform RNA loading. Similar results were
obtained with the day 7 samples (data not shown). The results of direct
quantitation of cytokine mRNA by a radio-imaging system (Ambis) are shown in
the graph. Each lane represented an RNA sample from a single animal. The
time points refer to the number of days after bleomycin or saline treatment on
day 0. The plotted data represent means 6 SE of results from three animals at
each time point. The increases (relative to respective controls) in bleomycin-
treated animals were statistically significant (P , 0.05) for days 7 and 14. The
bleomycin-induced increase in mRNA of both cytokines were significantly
inhibited (bleomycin plus control IgG versus bleomycin plus anti-IL-5 treated
groups) by treatment with anti-IL-5 antibodies at both time points studied.
Fig. 7. Effects on lung cellular cytokine antigen expression. Lung sections
from day 7 bleomycin-treated animals treated with either control IgG or
anti-IL-5 antibodies, were immunostained with anti-IL-5 (A), anti-TGF-b (B),
or anti-MCP-1 (C) antibodies to quantitate the number of cytokine-expressing
cells as described in Materials and Methods. Cytokine expression was
significantly elevated in bleomycin-treated lungs treated with control IgG. This
bleomycin-induced increase in cytokine-expressing cells was significantly
(P , 0.01) reduced in animals treated with anti-IL-5 antibodies for both time
points studied. Results are shown as means 6 SE with N 5 5 animals per group.
Control untreated lungs did not show detectable staining for any of these
cytokines, except for TGF-b staining localized primarily to epithelial cells.
Control IgG did not significantly alter lung cellular expression of cytokines in
bleomycin-treated animals (data not shown).
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monary fibrosis, and that this eosinophilia is important to the
overall fibrotic response.
The ability to suppress eosinophilia with anti-IL-5 antibod-
ies is not unexpected because previous reports in mice have
shown that blood eosinophilia induced by a parasite infection or
systemic administration of IL-2 can be abolished by the
administration of similar anti-IL-5 monoclonal antibodies [33,
60]. Previous studies have also reported on the efficacy of
similar anti-IL-5 antibodies in suppressing the lung airway
eosinophilia associated with antigen-challenged lungs in previ-
ously sensitized animals [33], but the results described here
represent the first report of such suppression of eosinophilia in
the lung parenchyma associated with lung injury and interstitial
as well as alveolar fibrosis. The eosinophil chemotactic activity
of IL-5 is well documented [31, 56, 57], hence the ability to
suppress eosinophilia with this antibody may be mediated via
this mechanism. However, the data presented cannot distin-
guish between its role in vivo as a cofactor (i.e., in conjunction
with other chemotactic factors, such as RANTES, MIP-1a,
eotaxin, etc.) or as a primary chemoattractant in its own right. In
addition, IL-5 is known to prolong and/or promote eosinophil
survival [20, 61, 62], thus providing another mechanism by
which neutralization of endogenous IL-5 activity could dimin-
ish lung eosinophil accumulation. With respect to the fibrotic
process itself, IL-5 is a well-known stimulator of eosinophils
with direct implications on their expression of such fibrogenic
cytokines as TGF-b and MCP-1 [8, 9, 63].
There is mounting evidence that the eosinophil is a key
source of many cytokines, including those with direct relevance
to the inflammatory and fibrotic responses. First, with regard to
the cellular source of IL-5 itself, the evidence indicates that it
is primarily restricted to the T lymphocyte and secondarily to
the eosinophil and mast cells [52, 53]. Consistent with this is
the demonstration that both T cells and mast cells are involved
in eosinophil accumulation in the lungs of allergic mice have
been documented [52, 53]. These results implicate a role for T
cells and IL-5 in the eosinophilic inflammatory response in the
lung. The findings in this study are consistent with these and
other recent studies [52, 54], which demonstrated that IL-4 and
IL-5 mRNA were expressed predominantly by T cells, and
suggested that TH2 cells were activated. A role for T cells in
bleomycin-induced and other models of pulmonary fibrosis has
been previously suggested [16, 54], which may be mediated by
T cell-derived IL-5 in those lesions characterized by eosinophil
infiltration. Indeed this may be a mechanism by which
neutralization of TNF-a activity results in abrogation of pulmo-
nary fibrosis [63]. However, there is some controversy as to the
exact role of T cells in this model of fibrosis [64]. A more direct
role of eosinophils vis-á-vis fibrosis is their importance as
sources of TGF-b, TGF-a, and other cytokines [9–11, 65, 66].
There is evidence that TGF-b is highly expressed in bleomycin-
induced pulmonary fibrosis, and at the peak of active fibrosis, a
key source of TGF-b1 is the eosinophil in this model [9]. Hence
prevention or diminution of eosinophilia by anti-IL-5 antibody
treatment effectively suppresses expression of these cytokines
in the lung, which are critical for fibrosis.
In addition to IL-5, IL-3 and granulocyte-macrophage colony-
stimulating factor are also capable of regulating several func-
tions of eosinophils, such as proliferation, adhesion, chemo-
taxis, and activation [12, 67, 68]. However, given the
effectiveness of IL-5 neutralization alone in suppressing fibro-
sis, these other cytokines may play secondary roles. Alterna-
tively, because the eosinophil is a key source of both TGF-b1
and MCP-1 in this model, suppression of eosinophilia by the
anti-IL-5 antibody may be sufficient to suppress both inflamma-
tion and fibrosis, by effectively inhibiting expression of the
cytokines essential for both processes [60]. Although IL-5 has
some effects on B cell function in the mouse, there is no
evidence of an important role for B cells in this model of lung
injury and fibrosis, despite some evidence for T cells. This plus
the relatively specific effects on eosinophil-function and the
eosinophil’s ability to express TGF-b1 and MCP-1 in this model
[8, 9] argues for the conclusion that IL-5 is important for
pulmonary fibrosis via its ability to promote eosinophilia, which
in turn is responsible for the full expression of an array of
cytokines critical for promoting the inflammation and fibrosis
that ensues.
On the basis of these observations in animals, it is tempting
to speculate about the potential utility of anti-IL-5 monoclonal
antibodies or other modes of suppressing eosinophil recruitment/
activation in treatment of patients with comparable forms of
lung injury, inflammation, and fibrosis, especially those with an
eosinophil component. Previous reports have suggested that the
presence of eosinophils may be quite widespread even in those
lung diseases without a demonstrable allergic component [13,
15, 68]. The possibility of using the TRFK-5 antibody in human
immunotherapy studies may become more feasible with the
production of humanized forms of the antibody [60].
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